Glasdegib Maleate is Used for treating newly-diagnosed acute myeloid leukemia in adult patients over 75 years old or with comorbidities. It was first introduced by Pfizer Inc in its drug Daurismo on Nov 21, 2018.

Glasdegib Maleate Patents

Given below is the list of patents protecting Glasdegib Maleate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Daurismo	US10414748	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate	Apr 13, 2036	Pfizer
Daurismo	US11168066	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate	Apr 13, 2036	Pfizer
Daurismo	US11891372	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate	Apr 13, 2036	Pfizer
Daurismo	US8148401	Benzimidazole derivatives	Jan 30, 2031	Pfizer
Daurismo	US8431597	Benzimidazole derivatives	Jun 29, 2028	Pfizer

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳